MOMalokhat Palvannazirovna Oltieva

Malokhat Palvannazirovna Oltieva

*This is an algorithmically generated author record based on publicly available information.

Malokhat Palvannazirovna Oltieva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan

    by Malokhat Palvannazirovna Oltieva, Dilfuza Abdullaevna Alieva, Sitorabonu Bahodir Kizi Abdusattorova, Iroda Pulatovna Sharipova, Jasur Ravshanovich Juraev, Tohirbek Shokir Ugli Shodiev, Erkin Isakovich Musabaev, Mirzarakhim Mirzakhakimovich Baynazarov, Khasanjon Kobiljon Ugli Odilov, Nurmuhammad Jaloliddin Ugli Jamoliddinov, et al.

    Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.